Not Signed In -
Indomethacin SR |
Indocin SR |
Clinical Trial: Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
This study is currently recruiting patients.
Verified by Pfizer September 2005
|
Purpose
To validate the analgesic efficacy and safety of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
| Condition | Intervention | Phase |
|---|---|---|
| Pain, Postoperative | Drug: celecoxib and ibuprofen SR | Phase III |
MedlinePlus related topics: Pain
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Multi-Center Study Comparing Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
Further Study Details:
Primary Outcomes: To validate the analgesic efficacy of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
Secondary Outcomes: To validate safety of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
Expected Total Enrollment: 132
Secondary Outcomes: To validate safety of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
Expected Total Enrollment: 132
Study start: October 2004
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Undergone uncomplicated orthopedic surgery or abdominal gynecological surgery under epidural anesthesia
- Baseline pain intensity of more than 45 mm as measured by VAS and a severity of pain graded as moderate or severe on the categorical pain intensity scale
Exclusion Criteria:
- A previous history of intolerance or hypersensitivity to any NSAIDs, cyclooxygenase inhibitor, sulfonamides, or any analgesic, or to drugs with similar chemical structures
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00150280
Pfizer CT.gov Call Center 1-800-718-1021
China
Pfizer Investigational Site, Beijing, 100034, China; Recruiting
Pfizer Investigational Site, Beijing, 100083, China; Recruiting
Pfizer Investigational Site, Beijing, 100020, China; Recruiting
Pfizer Investigational Site, Shanghai, 200025, China; Recruiting
Pfizer Investigational Site, Shanghai, 200032, China; Recruiting
China, Liaoning Province
Pfizer Investigational Site, Shenyang, Liaoning Province, 110001, China; Recruiting
Study chairs or principal investigators
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Study ID Numbers: A3191086
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00150280
Health Authority: China: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00150280
Health Authority: China: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Indocin SR (Drug Digest)
- Indomethacin SR (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
